Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
14.47
+0.11 (0.77%)
At close: Jun 2, 2026, 4:00 PM EDT
14.75
+0.28 (1.94%)
After-hours: Jun 2, 2026, 6:31 PM EDT
Amarin Corporation Revenue
Amarin Corporation had revenue of $45.13M in the quarter ending March 31, 2026, with 7.41% growth. This brings the company's revenue in the last twelve months to $216.76M, up 1.24% year-over-year. In the year 2025, Amarin Corporation had annual revenue of $213.65M, down -6.55%.
Revenue (ttm)
$216.76M
Revenue Growth
+1.24%
P/S Ratio
1.39
Revenue / Employee
$2,709,513
Employees
80
Market Cap
303.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 213.65M | -14.97M | -6.55% |
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | 429.76M | 200.54M | 87.49% |
| Dec 31, 2018 | 229.21M | 48.11M | 26.56% |
| Dec 31, 2017 | 181.10M | 51.02M | 39.22% |
| Dec 31, 2016 | 130.08M | 48.33M | 59.11% |
| Dec 31, 2015 | 81.76M | 27.55M | 50.84% |
| Dec 31, 2014 | 54.20M | 27.85M | 105.69% |
| Dec 31, 2013 | 26.35M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 500.00K | - | - |
| Dec 31, 2005 | 500.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.32B |
| Sanofi | 54.60B |
| Bristol-Myers Squibb Company | 48.48B |
| GSK plc | 43.29B |
| Biogen | 9.94B |
| Grifols | 8.58B |
| Organon & Co. | 6.16B |
| Scilex Holding Company | 33.86M |
AMRN News
- 6 days ago - New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia - GlobeNewsWire
- 4 weeks ago - Amarin Reports 2026 First Quarter Financial Results - GlobeNewsWire
- 6 weeks ago - Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 - GlobeNewsWire
- 2 months ago - Amarin highlights new recommendation for treatment of CV risk - TheFly
- 2 months ago - Amarin to present data in patients at extreme cardiovascular risk - TheFly
- 3 months ago - Amarin highlights recent data published on REDUCE-IT study - TheFly
- 3 months ago - Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities - TheFly
- 3 months ago - Amarin issues call to action for American Heart Month - TheFly